HIPEC

Free consultation

Find out whether HIPEC applies to your cancer at all

The review costs nothing and commits you to nothing. Send the histopathology report naming the tumor type and its origin, the most recent CT of the chest, abdomen and pelvis with the actual images, any PET or diagnostic laparoscopy findings, and a summary of the chemotherapy given so far. A surgeon will tell you whether the peritoneal disease looks completely removable and whether the evidence supports adding a heated wash in your tumor type.

What the letters stand for

HIPEC abbreviates hyperthermic intraperitoneal chemotherapy. Each word carries part of the meaning. Hyperthermic means heated, to between 41 and 43 degrees. Intraperitoneal means delivered into the abdominal cavity itself instead of into a vein. Chemotherapy means an ordinary cytotoxic drug, most often mitomycin C, oxaliplatin or cisplatin. Catheters go into the abdomen at the end of the cancer operation and connect to a pump and heat exchanger that circulate the drug solution around the organs for thirty to ninety minutes, holding the temperature steady while probes placed at several points report back. The fluid is then drained, any bowel joins are completed, and the abdomen is closed. Anesthesia continues throughout, so a patient experiences one operation rather than two.

Three names that are not HIPEC

Related names sit close enough to cause confusion. PIPAC, meaning pressurized intraperitoneal aerosol chemotherapy, sprays a drug into the abdomen through a keyhole and is a palliative treatment given repeatedly, without a major operation attached. Normothermic intraperitoneal chemotherapy delivers drug into the abdomen through a port over days or weeks, at body temperature. Neither is HIPEC, and a clinic using the terms interchangeably should be questioned closely.

Why heat, and why the abdomen

Poor blood supply is the defining feature of the peritoneum, the thin membrane lining the abdominal cavity. A drug given into a vein reaches deposits sitting on that surface at low concentration, and that is the reason ordinary chemotherapy performs badly against peritoneal spread while working perfectly well against the same cancer in the liver or the lung. Putting the drug directly into the cavity raises the concentration at the surface enormously, because the peritoneal membrane also limits how fast the drug escapes back into the bloodstream. Heat contributes three things. It damages cancer cells directly above about 41 degrees, it increases the uptake of several drugs into cells, and it appears to work synergistically with mitomycin and platinum compounds in laboratory conditions.

The one measurement everything else follows from

Drug delivered this way soaks into tissue to a depth of roughly one to three millimeters and no further, so a nodule of five millimeters is treated on its outer skin and left alive at its center. HIPEC is therefore a treatment for microscopic residue rather than for disease anyone can see, which is why it follows complete surgical clearance and never substitutes for it.

HIPEC never works alone

Every credible protocol pairs the wash with cytoreductive surgery, an operation lasting six to ten hours in which the surgeon strips the peritoneal lining from affected surfaces and removes whatever organs or segments of bowel the disease has invaded. Ninety minutes at the end of that belongs to the wash. The proportions matter, because they are inverted in most marketing. Surgical clearance does the heavy lifting. HIPEC adds to it, in some diseases substantially and in others not at all.

How to read a hospital page about it

A woman or man researching this treatment will find pages describing HIPEC as an advanced therapy that patients travel for, with the operation mentioned in a subordinate clause. Reverse that emphasis when assessing a hospital. The questions that predict a good outcome concern the surgery, meaning how completely the disease can be removed, how many of these operations the unit performs each year, and whether a peritoneal surface malignancy meeting reviews cases before anyone is offered a date.

Disease by disease, what the evidence shows

No general statement about HIPEC survives contact with the literature, because the answer changes completely with the cancer of origin.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Where the support is strongest

According to PubMed, an international registry analysis of 1924 patients with pseudomyxoma peritonei arising from an appendiceal mucinous tumor compared cytoreduction with the wash against cytoreduction alone. Weighted five-year survival reached 57.8 percent in the group receiving HIPEC and 46.2 percent in the group without it, a hazard ratio of 0.65, and the advantage held across optimal and suboptimal cytoreduction and across low-grade and high-grade disease (Kusamura et al, 2021).

Where it rests on registries alone

Peritoneal mesothelioma rests on registry data of a different kind. PubMed indexes a multi-institutional series of 405 patients treated with cytoreduction and HIPEC, in which median overall survival reached 53 months, with three-year and five-year survival of 60 and 47 percent, against a natural history historically measured in months. Grade 3 and 4 complications affected 31 percent, 2 percent died perioperatively, and receiving HIPEC was one of four factors independently associated with longer survival (Yan et al, 2009).

Where it was tested and failed

Colorectal cancer is where the confidence collapsed, and it collapsed in the disease that had provided most of the enthusiasm. Randomized evidence found that adding oxaliplatin HIPEC to a complete cytoreduction produced no survival gain in colorectal peritoneal disease while raising serious complications, and guidelines across Europe changed accordingly.

Prevention, tested directly

A second French trial then tested a related idea. Rather than treating established disease, it asked whether operating again on patients at high risk of developing peritoneal spread, and washing preventively, would keep the disease away.

Two in five patients suffered a serious complication in exchange for nothing measurable. That result deserves stating plainly, because preventive HIPEC is still offered in places, and the trial designed to prove its worth found the opposite.

Which drug, and does the choice matter

Protocols differ between units in the drug used, its dose, the temperature and the duration, and those differences are not cosmetic. In the pseudomyxoma registry, the survival advantage attached to specific regimens, with oxaliplatin combined with fluorouracil and leucovorin and with cisplatin combined with mitomycin both showing benefit, while mitomycin used alone carried nearly twice the odds of significant morbidity without the same survival signal.

How the three common drugs differ

Three agents account for the overwhelming majority of protocols in use, and each brings a different characteristic failure.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Different drugs also fail differently. Cisplatin is the one that damages kidneys, so renal function is checked carefully beforehand and fluids are run generously afterward. Mitomycin suppresses the bone marrow, which shows up as a falling blood count in the second week. Oxaliplatin brings its own electrolyte disturbances during the perfusion itself.

A pair of questions separates a protocol from an improvisation. Which drug will be used in your tumor type, and on what published basis. Whether the same protocol is applied to every patient regardless of the cancer, which would be a warning rather than a reassurance. Two further questions are worth the breath. Whether the unit follows a named consensus protocol or one of its own, and whether the perfusion temperature and duration it uses match what the published series for your tumor type actually tested. A unit running this treatment seriously answers all four without hesitating.

What happens in the ninety minutes

By the time the wash begins, the long part of the operation is finished and the abdomen holds no visible disease. What follows is a closed technical sequence that the patient sleeps through entirely.

1. Catheters and probes. Inflow and outflow catheters are positioned in the abdomen along with several temperature probes, so the team can confirm that heat reaches the diaphragm and the pelvis and not merely the middle.
2. Open or closed. In the open technique the abdomen is held apart while the surgeon stirs the fluid by hand to distribute it, and in the closed technique the skin is temporarily sutured and the fluid circulates under mild pressure. Both are in routine use and no trial has settled which is better.
3. The perfusion. Fluid circulates for thirty to ninety minutes depending on the drug, held at 41 to 43 degrees. Core body temperature rises, so the anesthesiologist actively cools the patient elsewhere while the abdomen is kept hot.
4. Drainage and reconstruction. The fluid is drained and the cavity rinsed. Only then are bowel joins completed, since a fresh join exposed to heated chemotherapy heals poorly, and the abdomen is closed with drains left in place.

Theater staff wear additional protection and the fluid is handled as cytotoxic waste, which occasionally alarms families who see it. The precautions protect the team from repeated occupational exposure across many cases and say nothing about the dose the patient receives.

Toxicity and the published rates

Separating the harm caused by the wash from the harm caused by a ten-hour operation is difficult, and honest units say so. What the series report is a combined figure.

Complications attributable to the drug are recognizable enough. Kidney injury follows cisplatin. A falling white cell count and platelet count follow mitomycin, typically in the second week, occasionally requiring transfusion or growth factor support. Nausea outlasts what the surgery alone would explain. Bowel joins leak more readily where they were made in a field that has been perfused, and experienced units therefore complete them after the wash. None of this argues against the treatment where the evidence supports it. It argues for being treated somewhere that handles the complications routinely.

Choosing where to have it

Cytoreduction with HIPEC has a documented learning curve and consumes a great deal of institutional resource, so the identity of the unit matters more here than in most operations. PubMed indexes a single-center series of 232 consecutive cytoreduction and HIPEC procedures performed at a tertiary cancer center outside the high-income world, reporting optimal cytoreduction in 94.4 percent, morbidity of 28.0 percent and treatment-related mortality of 3.5 percent, with ovarian cancer accounting for 56.5 percent of cases, pseudomyxoma 18.5 percent, colorectal 13.4 percent and mesothelioma 5.6 percent (Deo et al, 2021). Read that case mix closely, because it describes what a working peritoneal program actually treats. Two conclusions follow for an international patient. Results comparable to established Western centers are achievable outside them, where a protocol-driven multidisciplinary program exists. And the caseload of a genuine program is dominated by ovarian and appendiceal disease, so a unit describing colorectal HIPEC as its principal activity is describing an indication the randomized evidence does not support.

Four questions separate a genuine program from a piece of equipment.

• Annual volume of cytoreduction with HIPEC, counted as cases performed in the last twelve months rather than as years elapsed since the machine was installed.
• Whether a dedicated peritoneal surface malignancy meeting, with a surgeon, a medical oncologist, a radiologist and a pathologist in the room, reviews every case before an offer is made.
• Which drug protocols are used, for which tumor types, and on what published basis.
• The unit's own rate of complete cytoreduction, which is the number that predicts survival.

The weeks afterward

Intensive care follows for one to three days as a matter of planning, since fluid shifts after a long peritoneal operation are large and body temperature has been deliberately manipulated, and the ward stay that follows commonly runs one to three weeks. Feeding restarts slowly because bowel handled for many hours takes days to wake up, and nutrition goes in through a vein during the interval. Monitoring after the wash is drug-specific, and it does not stop at discharge.

• Blood counts, checked repeatedly through the second week where mitomycin was used.
• Kidney function, where cisplatin was the drug.
• Both of those again after you have gone home, on a schedule agreed before you leave rather than improvised afterward.

Fatigue is the symptom patients underestimate most. It persists for two to three months and longer where systemic chemotherapy resumes, the long abdominal wound needs three months before it has real strength, and feeling recognizably yourself again takes somewhere between three and six months in an uncomplicated recovery. Where a stoma was formed during the operation, managing it becomes its own process and needs a specialist nurse near where you live.

Planning a trip around it

Budget four to six weeks abroad. The wash adds ninety minutes to a day that already runs to eight or ten hours, and the recovery belongs to the operation rather than to the chemotherapy, which is why the trip is shaped the way it is.

Where the weeks actually go

Nobody should make this trip alone.

Something gets forgotten in almost every case, and it falls into two categories. Blood count and kidney function monitoring has to continue after you fly home, so the schedule and who performs it needs settling before departure. The tests themselves can be done anywhere. What matters is that somebody who knows what was given reads them, and here the coordinator who handled your case stays reachable on the same WhatsApp number once you are home, with results and imaging reviewed at no charge. And if a stoma was formed, supplies and a trained nurse have to be organized at home in advance, because arriving back without either is a genuinely difficult position.

What moves the price

Perfusion itself accounts for a small share of the total. Theater hours for an operation running to eight or ten, the perfusion machine and its disposable circuit, the cytotoxic drug, intensive care nights, and the pathology on multiple specimens together account for most of a quote, and the number of intensive care nights is both the largest single variable and the one nobody knows in advance. How much has to be removed sets the baseline, since a clearance involving three organ resections and bilateral diaphragm stripping consumes far more of everything than one clearing a limited area. Establish four things before accepting a quote. Whether HIPEC sits inside the figure or beside it, how many intensive care nights the quote assumes and what each additional night costs beyond that number, since a stay that runs a week longer than planned is the commonest way a package turns into a larger bill than anyone discussed. What happens financially if the abdomen is opened, more disease is found than the imaging showed, and the surgeon closes without proceeding. And whether stoma supplies and the first follow-up are covered.

Only a surgeon who has reviewed your own scans can answer any of it. That review costs nothing.

Back home, and the follow-up

Take the operative note, the completeness of cytoreduction score, the full histopathology, a written record of which drug was used at what dose and temperature and for how long, and a copy of the postoperative imaging. That drug record matters more than patients expect. An oncologist deciding what systemic treatment to give next needs to know what has already been delivered and by which route.

Once you are home, follow-up runs on two tracks. Surveillance imaging of the abdomen and chest continues at intervals over years near where you live, alongside tumor marker tests where they were raised at diagnosis, while systemic chemotherapy resumes once the wound tolerates it, on a judgment the surgical and medical oncology teams reach together.

Remote follow-up with the operating team earns its keep through the first months, because a scan reported near home showing something unexpected in the operated field is far easier to interpret for the people who were in the room than for a radiologist meeting your anatomy for the first time on a screen.

Frequently asked questions